



United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/628,186	07/28/2000	Paul Chinn	P 037003 0280721	2673
7590 05/26/2004		EXAMINER		
Robin L. Teskin			SAUNDERS, DAVID A	
Shaw Pittman 2300 N Street, N. W.			ART UNIT	PAPER NUMBER
Washington, DC 20037-1128			1644	
			DATE MAILED: 05/26/2004	1

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s) Group Art Unit		
Office Action Summary	628,186	CMIN	in Right	
Onice Action Summary	Examiner SAUN	1) 52 / 16	p Art Unit	
—The MAILING DATE of this communication appea	rs on the cover shee	t beneath the correspo	ndence address—	
Period for Reply				
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TOF THIS COMMUNICATION.	O EXPIRE	MONTH(S) FROM	THE MAILING DATE	
 Extensions of time may be available under the provisions of 37 CFR of from the mailing date of this communication. If the period for reply specified above is less than thirty (30) days, a real find period for reply is specified above, such period shall, by default, Failure to reply within the set or extended period for reply will, by state 	eply within the statutory mir expire SIX (6) MONTHS f	nimum of thirty (30) days will rom the mailing date of this	be considered timely.	
Status				
☐ Responsive to communication(s) filed on 4/5/	,4			
☐ This action is FINAL .				
 Since this application is in condition for allowance except accordance with the practice under Ex parte Quayle, 193 			erits is closed in	
Disposition of Claims				
Delaim(s) 1-16, 18, 49-63	•	is/are pending	in the application.	
Of the above claim(s)		is/are withdray	wn from consideration.	
☐ Claim(s)		is/are allowed		
M Paim(s) 1-4 6-8 10-13184	952-55 6	U -63 is/are rejected	· 	
$\frac{\text{Claim(s)}}{\text{Claim(s)}} \frac{1-4}{5}, \frac{6-8}{9}, \frac{10-13189}{15-1650-57}$	56-59	is/are objected	i to.	
☐ Claim(s)		•	restriction or election	
Application Papers		requirement.		
☐ See the attached Notice of Draftsperson's Patent Drawin	g Review, PTO-948.			
☐ The proposed drawing correction, filed on	is 🗆 approved	d □ disapproved.		
☐ The drawing(s)-filed on is/are object	ted to by the Examine	r		
☐ The specification is objected to by the Examiner.				
☐ The oath or declaration is objected to by the Examiner.				
Priority under 35 U.S.C. § 119 (a)-(d)				
 □ Acknowledgment is made of a claim for foreign priority us □ All □ Some* □ None of the CERTIFIED copies of □ received. 	the priority documents	have been		
 □ received in Application No. (Series Code/Serial Number □ received in this national stage application from the Interest 				
*Certified copies not received:				
Attachment(s)				
☐ Information Disclosure Statement(s), PTO-1449, Paper N	lo(s)	Interview Summary, P	ГО-413	
Wotice of Reference(s) Cited, PTO-892		☐ Notice of Informal Patent Application, PTO-152		
☐ Notice of Draftsperson's Patent Drawing Review, PTO-94	. 8	∃ Other	<u> </u>	
Office	e Action Summary			

U. S. Patent and Trademark Office PTO-326 (Rev. 9-97)

Part of Paper No.

Application/Control Number: 09/628,186

Art Unit: 1616

The amendment of 4/5/04 has been entered. Claims 1-16, 18, 49-63 are pending and under examination.

The amendment and urgings have overcome 112, first and second paragraph rejections of record. The examiner considers recitation of "at least about" in claims 52-55 to represent a rounding off from three to two significant figures.

A new basis of prior art rejection is stated supra.

Claims 1-4, 6-8, 10-13, 18, 49, 52-55 and 60-63 are rejected under 35 U.S.C. 102(b) as being anticipated by Albert et al (5,650,134).

Albert et al show somatostatin peptides conjugated at their N-terminal, to a chelating moiety. These compounds thus fall within the scope of the instantly recited "peptide" and "ligand" (since somatostatin peptides bind to receptors; see col. 1, line 10).

Example 11 shows the limitations of instant claim 1. The radiochemical purity is 99.5% (col.19, lines 46-47); Examiner takes "radiochemical purity" to be equivalent to "radioincoporation," since applicant has argued such in the response of 4/5/04.

The examiner calculates the specific activity as approx. 800mci/mg. See attached sheet of calculations. Therein, examiner has estimated the m.w. of the chelator peptide conjugate (compound of Example 3) as approx. 2000g. The octreotide moiety is estimated to be approx. 880g (taking 110g as the av. m.w. of an amino acid residue). The examiner also guesstimates the m.w. of the linker and chelater to be approx 1000. The peptide and chelating moieties together thus add up to 1880g; and this is rounded-off to 2000g. The examiner has no time to calculate the actual m.w. by

Application/Control Number: 09/628,186

Art Unit: 1616

adding up the atomic weights of each constituent of the compound of example 3. If examiner has over estimated the m.w. by a factor of two, then the calculated specific activity would be 1600 mci/mg. If examiner has under estimated the m.w. by a factor of two, then the calculated specific activity would be 400mci/mg. In any case, the calculated values well exceed instantly recited "5mci/mg."

Instant dependent claims 2-4 are included since example 11 shows 90 Y as the isotope. Claims 6-7 and 49 are included because Albert et al incubate for three minutes (col.19, line 43). Claim 18 is included since compound of Ex. 3 has a DTPA derivative as the chelating group. Claims 10-13 are included, since the 0.1M NH40AC solution at pH 5.0 (col.19, line 42) is considered to provide acceptable pH and buffering conditions. The incubation at room temperature (col.19, line 43) is consistent with "about 25 degrees C."

Claims 52-55 and 62-63 are included since all recited values are consistent with the disclosed radiochemical purity of 99.5%.

The binding specificites recited in claims 18 and 60-61 are considered consistent with the disclosure that the chelating group is attached to an amino group which does not significantly interfer with or prevent receptor binding of the thus modified peptide (col.1, lines 22-24).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to David A. Saunders, PhD whose telephone number is

Application/Control Number: 09/628,186

Art Unit: 1616

Page 4

571-272-0849. The examiner can normally be reached on Monday-Thursday from 8:00a.m to 5:30p.m. The examiner can also be reached on alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan, can be reached on 571-272-0841. The fax phone number for the organization where this application or proceeding is assigned is 571-273-1600.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Saunders/tgd

May 11, 2004

David Saunden DAVID SAUNDERS PRIMARY EXAMINER ART UNIT 182/644

628186 ATTACHMENT

CALCULATION OF SPECIFIC ACTIVITY OF 90Y LARELED COMPOUND (5,650,134, EXAMPLE 11)

O.16 mCi got ADDED TO 11 ML OF 9 MM CHELATING PEPTIDE (COMPOUND OF EX. 3).

ASSUME M.W. OF COMPOUND is CA. 2000 g.

THE NO, OF MOLES OF COMPOUND PRESENT IN

 $\frac{11 \text{ WL}}{10^{6} \text{ WL/L}} \times 9 \times 10^{-6} \text{ mol/L} =$ $\frac{99 \times 10^{-6} \times 10^{-6} \text{ mol}}{10^{2} \times 10^{-12}} = \frac{10^{-10} \text{ mols}}{10^{2} \times 10^{-12}}$

OF COMPOUND

ASSUMING 2000 g. WW., ONE HAS

 $10^{-10} \text{ mol } \times 2000 \text{ y/ml} = 2 \times 10^{-7} \text{ g}$ $= 2 \times 10^{-4} \text{ mg}$

SPECIFIC ACTIVITY IS THEN:

0.16 mCi = 16 × 10-2 mCi = 8 mCi = 800 mCi 2 × 10-4 mg = 2× 10-4 mg = 10-2 mg. mg